Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9879747 | 0.75 | MEN1 (0.32) | — | |
| SCHEMBL11769031 | 0.72 | TSHR (0.32) | — | |
| SCHEMBL9489314 | 0.69 | FDPS (0.36) | — | |
| SCHEMBL1426567 | 0.66 | OPRD1 (0.35) | OPRD1CA2CHKA | |
| SCHEMBL10817755 | 0.66 | — | — | |
| SCHEMBL11310538 | 0.66 | CHRM5 (0.37) | OPRD1 | |
| SCHEMBL2577695 | 0.65 | MEN1 (0.33) | CA2CHKA | |
| SCHEMBL175415 | 0.65 | MEN1 (0.33) | — | |
| SCHEMBL861270 | 0.65 | MEN1 (0.33) | — | |
| SCHEMBL10832743 | 0.65 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343971-B2 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-03-08 | — | — | US | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| CN-1812980-B | Piperidinyl-and piperazinyl-alkylcarbamate derivatives, their preparation and their use as pharmaceuticals | SANOFI AVENTIS | 2011-04-06 | — | — | CN | disclosed |
| CN-101712660-A | Piperidinyl-and piperazinyl-alkylcarbamate derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2010-05-26 | — | — | CN | disclosed |
| CN-1812980-A | Piperidinyl-and piperazinyl-alkylcarbamate derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059007-A1 | Pharmacologically-active vanilloid carbamates | FAAH, FAAH2, TRPV1 | OPRD1 92/4885CA2 354/4885CHKA 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.